Experts unpack IMfortis data on intensifying atezolizumab maintenance after induction chemoimmunotherapy in extensive-stage small cell lung cancer.
First-Line Maintenance Strategies in Extensive-Stage Small Cell Lung Cancer
IMforté data show larotrectinib plus atezolizumab maintenance extends PFS and OS in extensive-stage small cell lung cancer—real-world considerations.
Experts weigh IMfortis data, side effects, and patient selection as lurbinectedin-atezolizumab maintenance reshapes extensive-stage SCLC care.
Experts weigh brain metastases limits in IMFORTA and share real-world tips for maintenance lurbinectedin plus atezolizumab.
Experts weigh maintenance options after chemo-immunotherapy in extensive-stage SCLC, navigating brain mets, cytopenias, and real-world care barriers.
Relapsed small cell lung cancer care evolves as tarlatamab boosts survival but needs CRS/ICANS monitoring, while lurbinectedin offers simpler dosing.
Experts explore biomarkers, sequencing, and access strategies for extensive-stage small cell lung cancer maintenance, spotlighting tarlatamab, ADC combos, and clinical trials.
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5